CNS Pharmaceuticals Statistics
Total Valuation
CNSP has a market cap or net worth of $339,141. The enterprise value is -$8.77 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNSP has 455,162 shares outstanding.
| Current Share Class | 455,162 |
| Shares Outstanding | 455,162 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +153.86% |
| Owned by Insiders (%) | 2.29% |
| Owned by Institutions (%) | 15.07% |
| Float | 5.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.94 |
| Quick Ratio | 4.69 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -999.47 |
Financial Efficiency
Return on equity (ROE) is -477.53% and return on invested capital (ROIC) is -281.74%.
| Return on Equity (ROE) | -477.53% |
| Return on Assets (ROA) | -127.31% |
| Return on Invested Capital (ROIC) | -281.74% |
| Return on Capital Employed (ROCE) | -143.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.12M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.58% in the last 52 weeks. The beta is 0.75, so CNSP's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -98.58% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 3.50 |
| Relative Strength Index (RSI) | 34.98 |
| Average Volume (20 Days) | 195,369 |
Short Selling Information
The latest short interest is 399,235, so 87.71% of the outstanding shares have been sold short.
| Short Interest | 399,235 |
| Short Previous Month | 461,109 |
| Short % of Shares Out | 87.71% |
| Short % of Float | 7.34% |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.69M |
| Pretax Income | -17.46M |
| Net Income | -15.61M |
| EBITDA | -15.69M |
| EBIT | -15.69M |
| Earnings Per Share (EPS) | -$176.26 |
Full Income StatementBalance Sheet
The company has $13.05 million in cash and $210,673 in debt, giving a net cash position of $12.84 million or $28.20 per share.
| Cash & Cash Equivalents | 13.05M |
| Total Debt | 210,673 |
| Net Cash | 12.84M |
| Net Cash Per Share | $28.20 |
| Equity (Book Value) | 10.97M |
| Book Value Per Share | 44.71 |
| Working Capital | 10.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.16 million and capital expenditures -$4,188, giving a free cash flow of -$17.17 million.
| Operating Cash Flow | -17.16M |
| Capital Expenditures | -4,188 |
| Free Cash Flow | -17.17M |
| FCF Per Share | -$37.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
